Literature DB >> 7880394

Expression of intercellular adhesion molecule-1 (ICAM-1) on cultured human endometrial stromal cells and its role in the interaction with natural killers.

P Viganó1, R Pardi, B Magri, M Busacca, A M Di Blasio, M Vignali.   

Abstract

PROBLEM: Recent evidence emphasizes the role of natural killer cells (NKs) as potential effectors of peritoneal immune surveillance directed against the outgrowth of endometrial cells, refluxed with menstrual debris, in ectopic sites. This NK-mediated cytotoxicity toward autologous endometrial antigens seems to be significantly decreased in endometriosis patients.
METHOD: We set up experiments to clarify which molecules are involved in NK-endometrial cell interaction. In particular, we evaluated the surface expression and functional activity of intercellular adhesion molecule-1 (ICAM-1), a cell surface glycoprotein that has been identified as one of the ligands for lymphocyte function-associated antigen-1 (LFA-1), present on almost all leucocyte cell types. Immunofluorescence flow cytometry was used to assess ICAM-1 expression on resting and IL 1 beta-activated endometrial stromal cells in culture. Dermal fibroblasts were used as control cells. Cytotoxicity and binding assays by 51Cr release in presence and absence of a specific monoclonal antibody (mAb) against ICAM-1 were then performed in order to determine the effect of this molecule on NK-mediated cytotoxic and binding activity toward endometrial stromal cells.
RESULTS: The results of this study indicated that ICAM-1 expression on endometrial stromal cells seems to be constitutively higher than on dermal fibroblasts and can be up-regulated upon exposure to IL 1 beta. Furthermore, a mAb against ICAM-1 strongly inhibits the binding but not the cytotoxicity of NKs toward endometrial cells. No difference in the expression of this molecule was observed throughout the cycle.
CONCLUSIONS: The presence of ICAM-1 on human endometrium might relate to the action of the immunocompetent cells in human specific reproductive events.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7880394     DOI: 10.1111/j.1600-0897.1994.tb01104.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  6 in total

1.  2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis.

Authors:  Christian M Becker; Nadine Rohwer; Tae Funakoshi; Thorsten Cramer; Wanja Bernhardt; Amy Birsner; Judah Folkman; Robert J D'Amato
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

2.  Peritoneal fluid levels of immunoreactive corticotropin-releasing factor (CRF) and CRF-binding protein (CRF-BP) in healthy and endometriosic women.

Authors:  P Florio; M Busacca; M Vignali; P Viganò; R J Woods; P J Lowry; A R Genazzani; S Luisi; M Santuz; F Petraglia
Journal:  J Endocrinol Invest       Date:  1998-01       Impact factor: 4.256

3.  Endometriotic cell culture contamination and authenticity: a source of bias in in vitro research?

Authors:  Andrea Romano; Sofia Xanthoulea; Elisa Giacomini; Bert Delvoux; Eugenia Alleva; Paola Vigano
Journal:  Hum Reprod       Date:  2020-02-29       Impact factor: 6.918

4.  Effects of miR-363 on the Biological Activities of Eutopic Endometrial Stromal Cells in Endometriosis.

Authors:  Manman Nai; Yingying Zhang; Lei Li; Yuxi Jin; Yangge Li; Luwen Wang; Chenchen Ren
Journal:  Biomed Res Int       Date:  2022-03-26       Impact factor: 3.411

5.  Interplay between Misplaced Müllerian-Derived Stem Cells and Peritoneal Immune Dysregulation in the Pathogenesis of Endometriosis.

Authors:  Antonio Simone Laganà; Emanuele Sturlese; Giovanni Retto; Vincenza Sofo; Onofrio Triolo
Journal:  Obstet Gynecol Int       Date:  2013-06-13

Review 6.  Adhesion in Physiological, Benign and Malignant Proliferative States of the Endometrium: Microenvironment and the Clinical Big Picture.

Authors:  Emily J Rutherford; Arnold D K Hill; Ann M Hopkins
Journal:  Cells       Date:  2018-05-16       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.